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Abstract: Duchenne Muscular Dystrophy (DMD) is a fatal genetic muscle wasting disease with no
current cure. A prominent, yet poorly treated feature of dystrophic muscle is the dysregulation
of energy homeostasis which may be associated with intrinsic defects in key energy systems and
promote muscle wasting. As such, supplementative nutriceuticals that target and augment the
bioenergetical expansion of the metabolic pathways involved in cellular energy production have
been widely investigated for their therapeutic efficacy in the treatment of DMD. We describe the
metabolic nuances of dystrophin-deficient skeletal muscle and review the potential of various
metabogenic and nutriceutical compounds to ameliorate the pathological and clinical progression
of the disease.
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1. Introduction
Characterised as the most severe and aggressive form of all the muscular dystrophies, Duchenne
Muscular Dystrophy (DMD) results from a gene mutation at position 21 on the X chromosome and
consequently, absent expression of the cytoskeletal protein dystrophin [1]. The loss of dystrophin
expression from skeletal muscle and neuronal tissue in which it is normally present as part of a
transmembrane protein complex, induces chronic and progressive skeletal muscle wasting which
is fatal in all cases. The etiology of the disease is intimately linked to the cytostructural role of
dystrophin in providing stability to the sarcolemma, particularly during contraction; regulating
the proper expression of components of the sarcolemmal Dystrophin Protein Complex (DPC); and,
consequently, maintaining appropriate homeostatic transmembrane ion gradients and cell signaling
functionality [2–4]. It is widely reported in the literature that the secondary molecular mechanisms
ultimately leading to muscle degradation include abnormal calcium (Ca2+) homeostasis [5,6];
Ca2+-induced necrosis [7]; mitochondrial dysfunction and cellular energy perturbations [8–12]; and
satellite cell (stem cells that repair damaged skeletal muscle) exhaustion [13,14]. As skeletal muscle
regeneration fails to match degeneration rates and inflammatory activity persists, skeletal muscle
becomes infiltrated with fat and connective tissue which limits function and leads to the loss of
ambulation in the teenage years [15,16]; ultimately fibrosis of the diaphragm and heart ensues causing
respiratory dysfunction, cardiomyopathy and death by the third decade of life [17,18].
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Impaired energy metabolism has been historically, and again more recently, regarded in
the literature as a key player in the degeneration of dystrophin-deficient muscle (for review
see [19]). While a strong rationale exists in support of this bioenergetical dysregulation being a
fundamental consequence of increased demand for ATP-dependent intracellular Ca2+ buffering and
satellite cell-mediated muscle repair, it has alternatively been suggested that metabolic impairments
may be linked to the DMD genotype [11,20]. Various metabolic defects have been reported in
dystrophin-deficient skeletal muscle, affecting glycolysis, fatty acid metabolism, the tricarboxylic acid
(TCA) cycle, mitochondrial electron transport chain and the purine nucleotide cycle (PNC) [21–27].
Moreover, our group, along with others [8,10,28], has recently demonstrated an impaired capacity
for dystrophin-deficient muscle to produce ATP [12]. Collectively, these deficits amount to a 50%
reduction in ATP content within dystrophin-deficient myofibres from human patients and animal
models [8].
Gene and stem cell therapies represent the only potential cures for DMD, yet, some 20 years
following identification of the genetic defect, appropriate curative therapies are not a mainstream
treatment [29–31]. Currently, DMD patients are treated somewhat successfully with the corticosteroid
prednisolone, which while providing therapeutic value to the majority of sufferers, is not without
side effects [32]. Thus, treatment protocols that reduce the severity and progression of muscle
wasting must continue to be rigorously researched. Since dystrophin-deficient skeletal muscle is
underscored by a reduced capacity for energy biosynthesis, and this leaves muscle fibres ill-equipped
to buffer the pathophysiological cascade induced by the absence of dystrophin expression, targeting
the energy-producing pathways with therapeutic intervention seems logical. Indeed, a solid
body of literature has investigated the therapeutic potential of energy-promoting nutriceutical and
metabogenic supplements for the treatment of DMD. These studies are reviewed here in.
2. Dysregulation of Energy and Protein Metabolism in DMD
Both historically and more recently, DMD has been regarded as a disease of impaired myofibre
energy status, with resting ATP levels being half that of healthy control muscle [8,28] and the ATP
production capacity of dystrophic mitochondria demonstrably impaired [9–12]. These deficits are
evident in skeletal muscle from human DMD patients as well as from the genetically homologous mdx
mouse model of the disease [33,34]. Adequate production of ATP is essential to maintain the integrity
and function of all cells, and as such, it is synthesized immediately via the creatine phosphagen
system, and continuously via the metabolism of glucose via glycolysis and fatty acids via β-oxidation.
Generated pyruvate (glucose metabolism) and acetyl CoA (fat metabolism) are subsequently shuttled
into the linked TCA cycle and electron transport chain in the mitochondria and ATP is generated via
the process of oxidative phosphorylation (OXPHOS). Besides the direct uptake of glucose by the
glucose transporter (GLUT), glucose can be metabolically extracted from stored glycogen, and/or
synthesized from pyruvate, amino acids (AAs) and lactate when blood glucose levels deplete. Skeletal
muscle tissue also relies heavily on alternative pathways for ATP production in that of the cytoplasmic
pentose phosphate pathway (PPP).
Our group has previously shown a reduced propensity for NADH redox (Complex
I)—compared to FADH2 redox (Complex II)-stimulated OXPHOS in mdx mitochondria [12]—albeit
both states were depressed compared to healthy control mitochondria. This suggests in the first
instance that mdx mitochondria display a reduced capacity for pyruvate flux-mediated OXPHOS,
which likely reflects an inherent reduced capacity for glycolytic flux in vivo. Our data is consistent
with several studies that have demonstrated a reduced capacity for glycolysis [21–25] and reduced
expression of the cellular glucose uptake and glycolytic flux regulator, neuronal nitric oxide synthase
(nNOS). nNOS normally co-localises with dystrophin at the sub-sarcolemma [35,36]. In the absence
of dystrophin expression, nNOS becomes a target of hyper-activated calpains leading to reduced
expression and nNOS-mediated NO production. As nNOS and/or nNOS-generated NO are strong
regulators of glucose uptake and flux through the glycolytic enzyme cascade (particularly during
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muscle contraction) [37,38], it is likely that reduced substrate availability is a precursor to energy
system de-regulation. However, defects in fat oxidation have also been reported [39–45], which in
conjunction with our data, suggests a fundamental defect at the mitochondrial level that induces
deregulation of all metabolic systems. It is the working hypothesis of our group, that mitochondrial
pathology forms the basis of DMD aetiology alongside dystrophin-deficiency [19] (Figure 1), such that
much like the damage following eccentric muscle injury (Figure 1A), dystrophin-deficiency-mediated
damage could be mitigated if ATP availability was sufficient. Teamed with mitochondrial pathology,
however, a “two-hit” scenario exists whereby a reduced capacity for ATP synthesis and perturbations
in myofibre energy homeostasis (i.e., metabolic stress) exacerbates muscle degeneration, reduces
regenerative capacity and ultimately, promotes muscle wasting (Figure 1B). During metabolic
stress, a cell signaling cascade is initiated in skeletal muscle which inhibits protein synthesis and
promotes muscle catabolism via autophagy. As such, ATP utilization is spared and AAs stored
as skeletal muscle tissue are made available to metabolism to increase ATP synthesis and restore
energy homeostasis [46]. This is achieved predominantly through the activation of adenosine
monosphosphate (AMP)-activated protein kinase (AMPK) which is phosphorylated by rising AMP
levels. It has been established that both increased AMPK and autophagic activity are a feature of
dystrophin-deficient skeletal muscle [47]. As such, a proportion of the muscular hypercatabolism
observed in dystrophin-deficient muscle may be attributable to autophagy. Consistent with this,
Rennie et al. [48] demonstrated a 2.5-fold increase in protein turnover and a 6.5-fold reduction
in capacity for muscle-specific protein synthesis in DMD patients that coincided with a 63%
increase in leucine oxidation. Okada et al. [49] also report higher urinary 3-methylhistidine
excretion as an indicator of increased protein turnover in DMD patients, and suggest that the
maintenance requirement of dietary protein intake is 70% higher in DMD patients compared to
healthy controls. Both metabolic stress and insufficient protein/AA intake are likely contributors
to an overall reduced capacity for muscle protein synthesis and the maintenance of muscle mass in
hypercatabolic dystrophin-deficient skeletal muscle. Indeed, AMPK activation is a strong inhibitor
of protein synthesis [50], while increased plasma AA concentration is a strong stimulator of it [51].
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Figure 1. The  role of ATP  in  the mitigation and  recovery of eccentrically‐induced damage  in  (A) 
healthy and (B) dystrophin‐deficient skeletal muscle fibres. Eccentric damage of healthy muscle (A) 
potentiates Ca2+ influx from the extracellular space and increases the intracellular Ca2+ concentration. 
Proteases and  lipases activated by Ca2+, cause damage  to  the contractile apparatus, mitochondria, 
sarcoplasmic  reticulum  and  the  muscle  membrane.  In  healthy  muscle,  Ca2+  uptake  into  the 
mitochondria  stimulates  oxidative  phosphorylation  and ATP  production  is  increased  to  support   
ATP‐fuelled  Ca2+  extrusion  pumps  in  the  muscle  membrane,  sarcoplasmic  reticulum  and 
mitochondria, thus restoring  intracellular Ca2+ homeostasis and mitigating the severity of damage. 















AAs  stored  in  muscle  protein  are  also  important  energy  reservoirs  and  act  as  substrates  for 
gluconeogenesis and TCA cycle intermediates to supplement energy metabolism during periods of 
substrate deprivation (i.e., starvation) and/or metabolic stress [58–60]. Several AA‐like molecules are also 
crucial  to  skeletal  muscle  maintenance  and  function,  such  as  creatine  (Cr)—which  functions 
importantly as a high‐energy storage molecule and stimulant of mitochondrial ATP production—
and taurine. 
Figure 1. The role of ATP in t itigation and recovery of e centrically-induc d damage in
(A) healthy and (B) dystrophin-deficient skeletal muscle fibres. Eccentric damage of healthy
muscle (A) potentiates Ca2+ influx from the extracellular space and increases the intracellular
Ca2+ concentration. Proteases and lipases activated by Ca2+, cause damage to the contractile
apparatus, mitochondria, sarcoplasmic reticulum and the muscle membrane. In healthy muscle,
Ca2+ uptake into the mitocho dria stimulates oxidative phosphorylation and ATP production is
increased to support ATP-fuelled Ca2+ extrusion pump i the muscle m mbrane, sarcoplasmic
reticulum and mitochondria, thus restoring intracellular Ca2+ homeostasis and mitigating the severity
of damage. ATP also fuels satellite cell replication and skeletal muscle repair, which is activated by the
inflammatory response. In dystrophin-deficient skeletal muscle (Figure 1B), the increased propensity
for membrane rupture during eccentric contraction causes the same, albeit amplified, degenerative
cascade. Teamed with mit chondrial dysfunction, however, ATP productio is insufficie t to fuel
the ATP-dependent buf ing of Ca2+ influx to mitigate damage—d gen rative activity is therefore
amplified. There is also a limited capacity for skeletal muscle repair due to the energy-demanding
nature of cell proliferation. The consequence is metabolic stress, progressive muscle degeneration,
insufficient repair of degeneration and muscle wasting.
3. Therapeutic Potential of Metabogenic and Nutriceutical Supplements
3.1. Amino Acids and Protein Isolates
In addition to their role as building blocks for protein synthesis, AAs directly orchestrate a
cell-signaling cascade that stimulates intracellular protein synthesis—especially in the case of the
essential AAs [52–54]. This occurs via activation of the phosphatidylinositol (PI) 3-kinase-mammalian
target of rapamycin (mTOR) signali g pathway in which AAs demonstrably act on various
target molecules to licit both activating and inhibit ry effect on mRNA translation and cellular
hypertrophy [55–57]. AAs stored in muscle protein are also i portant energy reservoirs and act
as substrates for gluconeogenesis and TCA cycle intermediates to supplement energy metabolism
during periods of substrate deprivation (i.e., starvation) and/or metabolic stress [58–60]. Several
AA-like molecules are also crucial to skeletal muscle maintenance and function, such as creatine
(Cr)—which functions importantly as a high-energy storage molecule and stimulant of mitochondrial
ATP production—and taurine.
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3.1.1. Creatine
Increasing intramuscular phosphocreatine (PCr) levels via oral Cr loading has been well
documented [61–63] and has become a mainstay of athletes seeking putative performance
enhancement—especially with respect to strength, speed and power. Various physiological benefits
have been attributed to increases in the total creatine (TCr = PCr + Cr) status of muscle, including:
(1) enhanced mitochondrial ATP flux via the PCr shuttle [64–67]; (2) stimulation of glycolysis [68,69];
(3) improved buffering of both the ATP:ADP ratio via the phosphagen system [70–72] and
intramuscular pH [73]; and (4) enhanced protein synthesis (particularly when accompanied with
resistance exercise) [74]. As such, several studies have examined the efficacy of Cr supplementation
as a therapeutic intervention in both human DMD patients [75–79] and in the mdx mouse model of
DMD [9,80,81].
In a randomized double-blind cross-over study, Louis et al. [78] examined the therapeutic efficacy
of a 3 g¨day´1 Cr supplementation protocol for 3 months in DMD patients and demonstrated
benefits in measures of muscle performance—specifically in doubling the time to fatigue at 75%
maximum voluntary contraction (MVC) and allaying the increase in total joint stiffness that was
observed in untreated controls over the 3-month trial. The authors did not observe increases in lean
body mass, reduction in serum CK levels or changes in creatinine excretion rate, suggesting that
Cr may provide alternative benefits aside from enhancing cellular energetics and preventing muscle
damage [78]. In a similar study with 30 DMD boys (50% of whom also maintained corticosteroid
treatment throughout), Tarnopolsky et al. [77] supplemented Cr at a dosage rate of 0.1 g¨kg´1¨day´1
for 4 months (followed by a 6 week washout phase and 4 months of placebo) and also reported
improvements in dominant hand-grip strength and the maintenance of strength over time, albeit
no improvement in functional task decline or measures of pulmonary function. A particularly
interesting feature of Tarnopolsky’s study was the finding of significantly increased fat-free mass
after a four-month supplementation protocol [77]. This suggests that in this trial, Cr supplementation
either promoted net muscle accretion or reduced the rate of muscle degradation induced by the
disease pathology. Cr supplementation, however, had no effect on body fat percentage [77].
More recently, Banerjee et al. [82] investigated the effect of Cr supplementation on skeletal muscle
bioenergetics. In a randomized, placebo-controlled (500 mg vitamin C) single blinded experiment,
steroid-naïve DMD boys were supplemented orally with Cr at a dosage rate of 5 g¨day´1 for 8
weeks. The study reported an increase in the PCr/Pi ratio, PCr content and ATP peaks (31P MRS) that
translated at a functional level, to increased strength in Cr-treated DMD patients [82]. This highlights
that Cr supplementation augments functional improvements by positively regulating skeletal muscle
energy homeostasis.
Beneficial effects have also been observed consistently in mdx skeletal muscle. Louis et al. [81]
supplemented mdx mice with Cr in both the food (47 g¨kg´1) and water (14 g¨L´1) supply for
30 days and reported a 12% increase in Extensor Digitorum Longus (EDL) TCr content that effectively
restored normal resting levels (as depicted by controls). This corresponded histologically with
a reduction in pseudohypertrophic muscle mass and mean fibre surface area. In this study, Cr
supplementation had no protective effect on susceptibility to stretch-induced fibre injury or the
accumulation of centrally nucleated (regenerative) fibres in adult EDL muscle. Cr supplementation
also induced a significant increase in half relaxation time (½ RT) in both mdx and normal mice and a
highly significant increase in the total Ca2+ content of the gastrocnemius muscle that was not observed
in Cr-supplemented normal mice [81]. This data suggests that Cr-supplementation failed to allay the
dystrophic phenotype.
Pulido et al. [80] has published the only study to date investigating the effect of Cr
supplementation on intracellular Ca2+ handling in dystrophic muscle. Cultured mdx myotubes
were supplemented in vitro with 30 mM Cr at the onset of myocyte fusion and cytoplasmic
Ca2+ was quantified using the Ca2+-specific fluorophore Fura-2. Cr was shown to significantly
inhibit dystrophy-induced sarcoplasmic elevations in Ca2+ concentration after several days of
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supplementation. This was attributed to enhanced SR Ca2+ ATPase activity, albeit direct
measurement of SR Ca2+ was not made and thus improvements in sarcolemmal and mitochondrial
ATPase activity could not be ruled out. Ca2+ influx rates remained unaffected between Cr-supplemented
and unsupplemented groups, indicating definite improvements in Ca2+ buffering capacity
rather than a reduction in entry [80]. This study most importantly demonstrated that
Cr-induced improvements in sarcoplasmic Ca2+ buffering and improved myotube survival
rates [80]. An extension of this research by Passaquin et al. [83] supported Pulido’s
findings, demonstrating delayed onset and reduced severity of initial degenerative cycles
in young mice, which was accompanied by enhanced mitochondrial oxidative function.
Whilst the findings of Pulido et al. [80] and Passaquin et al. [83] differ from those of
Louis et al. [81] with respect to the effects of Cr supplementation on skeletal muscle Ca2+
handling, it is possible that the absolute gastrocnemius Ca2+ concentration ascertained by
Louis et al. [81] is misrepresentative of the fact that Cr supplementation might increase cell survival
duration by increasing the buffering of Ca2+ from the sarcoplasm into subcellular compartments
and retaining it within. Thus whilst a greater net Ca2+ concentration of myofibres would be
observed, relative sarcoplasmic Ca2+ concentration would be significantly decreased by the better
Ca2+ buffering capacity afforded by Cr. That CK is demonstrably linked to the sarco(endo)plasmic
reticulum Ca2+ ATPase (SERCA) indeed indicates that improved uptake into the SR is likely [84,85],
and thus that maintaining energy homeostasis in fundamental to moderating the pathological
damage of dystrophin-deficient skeletal muscle.
Taken together, the collective data suggests that Cr supplementation has the ability to
offset the degenerative features of dystrophin-deficient muscle by improving PCr content, ATP
rephosphorylative capacity, mitochondrial function and Ca2+ compartmentalization within skeletal
muscle to reduce/offset damage. While the hallmark clinical signs of muscle degeneration (such as
serum CK and urinary creatinine excretion) are still evident in patients following Cr supplementation,
the functional improvements in strength and fatigability observed suggest that supplementative Cr
is still a valuable therapeutic adjunct to improve patient quality of life.
3.1.2. Glutamine
Glutamine is the most abundant free AA in the plasma and skeletal muscle. Glutamine has many
physiological roles within the body, but its effect on protein turnover is the most pertinent in relation
to DMD. Since glutamine is predominantly produced by the muscle, dystrophin-deficiency-induced
muscle degradation leads to a decrease in glutamine turnover and low intramuscular glutamine
concentration [86]. This results in a negative whole-body leucine balance [86]. With this in mind,
the need for extra glutamine for protein metabolism support may be increased in DMD patients.
The first study to demonstrate glutamine’s potential effect on whole body protein balance was by
Hankard et al. [87]. The study’s primary aim was to examine the acute anabolic effects of glutamine
ingestion on 6 young boys with DMD. Despite no effect on non-oxidative leucine disposal (a marker
of protein synthesis), oral glutamine supplementation (800 µmol¨kg´1¨L´1) decreased leucine and
glutamine release from protein degradation, in addition to glutamine de novo synthesis, suggesting a
possible protein-sparing effect in DMD children [87].
To confirm these initial findings, but also determine if a longer supplementation could be more
beneficial, Mok et al. [88] randomised 26 DMD boys to ingest either glutamine (0.5 g¨kg´1¨day´1)
or an iso-nitrogenous, nonspecific AA mixture (0.8 g¨kg´1¨day´1) for 10 days. The rate of
leucine appearance and endogenous glutamine due to protein breakdown (estimates of whole-body
protein degradation) were decreased in both groups following the 10 day supplementation
period. Interestingly, plasma glutamine and AA concentrations did not increase following the
supplementation period and the authors suggest that glutamine’s effect on whole-body protein
metabolism may not be solely driven by substrate availability. Alternatively, glutamine uptake by the
intestine might be sparing other AAs and substrates from degradation, and thus could be driving the
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protein-sparing effect in DMD [88]. To explain the molecular basis for glutamine’s anti-proteolytic
effect in DMD children, the same author and lab used animal models to demonstrate a reduction
in GSSG/GSH (the major regulator of the cellular redox potential and a widely used indicator of
oxidative stress) and ERK 1/2 activation (a signaling kinase involved in muscle breakdown) in
dystrophic skeletal muscle of young mdx mice following daily intraperitoneal injections of L-Gln
(500 mg¨kg´1¨day´1) or 0.9% NaCl for 3 days [89].
While these results are promising, it is important to determine if glutamine’s protein-sparing
effects could translate into functional benefits, but more importantly, clinically relevant benefits.
In a randomised controlled trial (RCT), ambulant DMD boys (n = 30) ingested both glutamine
(0.5 g¨kg´1¨day´1) and placebo (maltodextrin) in a cross-over design for a period of 4 months [90].
The study showed no improvements in walking speed and other functional tests, body composition
and markers of myofibrillar protein breakdown following the supplementation period. Despite some
limitations in the study (variability in functional measures, response to placebo in children in RCTs
versus adults), the routine use of glutamine in this population could not be supported. This was also
confirmed in another RCT trial that tested the efficacy of glutamine in DMD boys aged 4–10 years [91]
using a parallel trial to compare 6 months of oral glutamine (0.6 g¨kg´1¨day´1) (n = 19) with placebo
(n = 16). This study showed no significant effects on manual muscle testing scores of 34 muscle
groups, or on quantitative measures of muscle strength of bilateral elbow flexors and extensors, knee
flexors and extensors and grip. Therefore, despite previous experimental data in mdx mice [89,92] and
short term clinical studies showing improvements in protein metabolism and whole body strength,
especially in younger dystrophic males [87,88]; current evidence in RCTs is not convincing and clearly
warrants further investigation.
3.1.3. Taurine
Taurine is another free AA-like molecule that is abundant in skeletal muscle in addition to
several other highly metabolic tissues including brain and liver. Though the majority of taurine
formation occurs in the liver, other cells are also able to synthesise taurine from cysteine, including
kidney, brain and to a lesser extent, skeletal muscle [93]. Taurine exerts a wide spectrum of
actions including fluid concentration control and antioxidant and anti-inflammatory effects. In
skeletal muscle, taurine plays an integral role in ion channel function and Ca2+ homeostasis [94–97].
Similar to intramuscular glutamine, dystrophic muscles seem to be deficient in taurine, which is
likely a consequence of excess cysteine disposal [98]. Normalising taurine levels in dystrophic
muscles may help to stabilize membrane integrity and reduce inflammation and oxidative stress,
and therefore decrease muscle dystrophinopathy. Previous studies have demonstrated that treatment
of dystrophic muscles with taurine (10%, w/w in chow) is relatively safe, but importantly, can
lead to improvements in grip strength, prevention of exercise-induced muscle weakness and
restoration of Ca2+ homeostasis [99,100]. In a study designed primarily to determine the potential
of nuclear magnetic resonance spectroscopy as a tool to monitor histology, researchers showed that
in muscles of mdx mice treated with glucocorticoid, taurine levels were increased [101]. This could
suggest that taurine, in part, may be contributing to the improved pathology normally associated
with glucocorticoid treatment [101]. Recently, intramuscular taurine deficiency in mdx mice was
ameliorated by L-2-oxothiazolidine-4-carboxylate (OTC), a cysteine precursor, administration [98].
Mice received 0.5% (w/v) OTC in their drinking water for a period of 6 weeks (from 6 to 12 weeks
of age) which equates to approximately 100 µM of cysteine per day. Six weeks of OTC treatment
increased taurine content in the liver (similar extent as controls) and plasma of mdx mice which
resulted in a decrease in protein thiol oxidation (oxidative stress), decreased pathology and increased
forelimb grip strength.
Our own work has shown that 4 weeks of dietary taurine supplementation (3% w/v in drinking
water) increased taurine content in mdx mice [102]. This resulted in enhanced fatigue resistance and
better recovery of force development of muscles contracted ex vivo [102]. Given no alternations in
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calcium-handling proteins were observed, it is possible that improvements in metabolic function
contributed to the effects observed. Clearly further experimental work is needed to establish whether
these benefits in dystrophic animal models of DMD can be translated into human DMD patients, but
also to understand the precise cause of taurine deficiency and determine which taurine-enhancing
intervention is best able to afford functional and clinically significant benefit to DMD patients.
3.1.4. Arginine
As previously mentioned, the lack of dystrophin in skeletal muscle disrupts the recruitment of
nNOS to the sarcolemma which negatively affects endogenous skeletal muscle NO production. NO
is involved in many physiological roles including force production (excitation-contraction coupling),
blood flow autoregulation, myocyte differentiation, respiration, and glucose homeostasis [38].
Increasing NO can be achieved via administration of L-arginine (the substrate for nNOS). Using this
method, 4 month old female mdx mice were given L-arginine treatment (200 mg¨kg´1, intraperitoneal
injection) for 5 out of 7 days for 6 weeks. L-arginine treatment upregulated utrophin (another
cytoskeletal protein with over 80% homology with dystrophin) expression 2- to 3-fold in dystrophic
mdx muscles and lead to a 35% reduction in necrotic zones [103]. Additionally, when L-arginine
(0.375% in drinking water) is given in combination with Deflazacort (a glucocorticoid) for 3 weeks,
quadriceps muscles were spared from injury-induced regeneration, despite an increase in membrane
permeability following exercise [104]. Performance was also improved with an increase in the
distance (km) run voluntarily by individual mice. Although early results suggest a potential new
treatment for improving the quality of life for boys with DMD, similar to taurine, further clinical
trials need to be performed. This is especially true, as nNOS content is notably reduced to critically
low levels in the skeletal muscle of DMD patients [35,36], but variably, if at all, in mdx mouse skeletal
muscle. As L-arginine is a substrate for nNOS-mediated NO production, a lack of nNOS protein
would theoretically render supplementative therapy useless at increasing skeletal muscle NO levels.
Moreover, since L-arginine can have adverse side effects, other methods to increase NO, might be
preferable for NO-based therapy in muscular dystrophy [105].
Indeed a series of recent studies have demonstrated the efficacy of NO-donating non-steroidal
anti-inflammatory drugs (NSAIDS) in reducing muscle wasting and promoting regenerative
capacity in the mdx mouse model and in human DMD patients [106–109]. However, due to
the extremely short half-life of NO, there is a questionable capacity for highly reactive NO
donors to mediate effects outside of the vasculature. It is probable, therefore, that the beneficial
effect afforded by NO-donor-NSAID therapies is more likely related to a modulation of blood
flow/systemic O2 delivery and/or inflammatory/immunological pathways, and, therefore, skeletal
muscle regenerative capacity; rather than NO-mediated effects within the skeletal muscle itself.
Like NO-donor therapy, pharmacologically amplifying/extending the NO-mediated-cGMP signal
using the phosphodiesterase 5 (PDE5) inhibitors sildenafil (Viagrar) and tadalafil (Cialisr) could
be useful for circumventing the poor endogenous NO production caused by reduced nNOS content
to afford therapeutic efficacy in dystrophin-deficient skeletal muscle. In mdx mice, Percival et al. [110]
demonstrated that 14 weeks of sildenafil treatment significantly reduced damage to, and fibrosis
of, diaphragmatic skeletal muscle fibres. However, in a later study, the same group concluded that
therapeutic efficacy is not via metabogenic effects on the mitochondria as sildenafil treatment actually
reduced the ATP content of hind limb skeletal muscle. The body of literature since suggests that the
benefits of pharmacological NO-cGMP signal amplification lie at the vascular level, and in increasing
blood flow and O2 delivery to skeletal and cardiac muscle particularly during exercise [111,112].
Most interesting, is a recent randomized, double-blind, placebo-controlled, cross-over design clinical
study in BMD patients, which demonstrated no effect of sildenafil on exercise-induced blood flow,
functional tests, or skeletal muscle oxidative capacity; but rather concomitant deficiency of PDE5
receptor expression alongside nNOS deficiency in dystrophin-deficient skeletal muscle [113]. This
suggests that the propensity for pharmacological inhibition of PDE5 as a therapeutic target to
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enhance the NO-cGMP axis is diminished in human patients in particular. Thus alternative avenues
for enhancing NO production and downstream signaling pathways would be useful. Nutritional
supplementation of dietary nitrate has been consistently shown in the literature to increase the total
nitrate/nitrite/NO pool in skeletal muscle and generate NO independent of nNOS [114,115]. It may,
therefore be of therapeutic value to dystrophin-deficient skeletal muscle as an alternative means
of restoring endogenous NO production within skeletal muscle, as has been suggested in diabetic
skeletal muscle [116,117].
3.1.5. Whey Protein Isolates
An extract of soluble protein fractions from bovine milk, whey protein (WP) supplements
are popular as an established method of enhancing muscle anabolism and hence athletic
performance [118–120]. It has been suggested that WP offers considerable benefits over other high
quality protein sources by constituting a higher concentration of essential AAs (45–55 mg¨ 100 g´1) [121],
and thus conveying a higher biological value—descriptive of its ability to provide and retain
nitrogen in a balanced interplay of essential and non-essential AAs [122]. In comparison to the
other high quality dairy protein, casein, WP also claims a higher protein efficiency ratio (PER) of
2.6 versus 3.2, thus eliciting a larger rate of weight gain per gram of protein consumed over time [122].
Indeed, the unique physical properties of WP in the gastrointestinal system are likely to convey its
benefits—unlike casein that clots in the stomach resulting in slowed release into the small intestine,
and thus significant hydrolysis prior to absorption, WP immediately enters the small intestine in
which its progressive hydrolysis is relatively slow, providing a unique delivery of both AAs and
peptides [123,124]. Because of this difference, WP consumption elicits an acute peak in serum AA
concentration [124–126] that when accompanied with mixed macronutrients, demonstrably induces
increased rates of muscle protein synthesis and net gains in systemic protein deposition [126]. WP
may also offer various other benefits specific to its high concentration of both the sulphur-containing
AA cysteine for its immunological and anti-oxidant modulatory role [127], and branched-chain AA
leucine for its skeletal muscle protein regulating role [128,129].
Whilst there is no published data to date describing the effect of WP (or casein/other non-dairy
protein isolates) supplementation on skeletal muscle preservation in DMD patients, it is clear from
isolated AA supplementation trials (described previously) that increasing systemic AA status could
be of therapeutic benefit, particularly if the aforementioned hypothesis of dystrophinopathy-induced
AA deficit is true. We have preliminary data demonstrating that dietary supplementation of mdx mice
with WP (16% in chow), both alone and in combination with Cr monohydrate (1% in chow) (WP + Cr)
for 6 weeks, increases the total protein content of the gastrocnemius and diaphragm ([130]; Figure 2).
However, most interestingly, WP and WP + Cr supplementation significantly decreases the contractile
protein fraction of the total protein pool while inducing increases in the mitochondrial and structural
protein fraction in both gastrocnemius and diaphragm (Figure 2). Our preliminary data suggests that
in times of metabolic stress when mTOR signaling is inhibited by AMPK and downstream activators
drive mitochondrial biogenesis, AA uptake into cells is directed toward mitochondrial fission, growth
and function. Indeed, our data in healthy trained humans also suggests an augmentative effect of
WP on contractile protein accretion-independent force production [131]. While Cr supplementation
demonstrably induced greater increases in fibre size, contractile protein content and strength gains,
the force production gains observed following Cr + WP supplementation were independent of fibre
size [131]. We speculate that WP modulates contractile function via direct effects on the sarcoplasmic
reticular calcium-handling apparatus and/or mitochondrial ATP production, albeit we are yet to
confirm this in healthy humans or DMD patients/animal models. Considerable research would thus
be required to establish WP supplementation as a therapeutic adjunct for the treatment of DMD.
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Figure  2.  Subfractional  protein  distribution  following  dietary  Cr  and  WP  supplementation  in 
gastrocnemius (A) and diaphragm (B) from the mdx mouse model of DMD. Contractile proteins are 
indicated by dark grey bars, sarcoplasmic  reticular  (SR) proteins are  indicated by  light grey bars, 
mitochondrial  proteins  are  indicated  by  red  bars  and  the  remaining  protein  pool  (containing 
structural and nuclear proteins)  is highlighted by  the blue bars. Data  is expressed as  the mean % 
subcellular protein fraction of the total protein pool ± SEM. Significance was considered as p < 0.05 
compared to unsupplemented mdx control muscle and  is  indicated by asterisk whereby: * p < 005,   




CoQ10  is  an  essential  cofactor  found naturally  in practically  every  cell  in  the human body. 
CoQ10 is lipid‐soluble and primarily acts as an electron carrier in the mitochondrial respiratory chain. 
CoQ10  is  also  a  strong  antioxidant  which  is  able  to  reduce  oxidative  radicals  and  modulate   
the mitochondrial permeability transition pore (MPTP) which could potentially be of benefit in DMD 
muscle  to decrease mitochondrial Ca2+  accumulation,  swelling, dysfunction and mitochondrially‐
regulated  apoptosis  [132].  Previous  oral  forms  of CoQ10  have  had  limited  success  at  increasing 
mitochondrial CoQ10 content due to solubility issues, although recent advances in delivery (i.e., fast 
Figure 2. Subfractional protein distribution following dietary Cr and P supple entation in
gastrocnemius (A) and diaphragm (B) fro the mdx ouse odel of . Contractile proteins are
indicated by dark grey bars, sarcoplas ic reticular (SR) proteins are indicated by light grey bars,
itochondrial proteins are indicated by red bars and the remaining protein pool (containing structural
and n clear proteins) is highlighted by the blue bars. Data is expressed as the mean % subcellular
protein fraction of the total protein pool ˘ SEM. Significance was considered as p < 0.05 compared
to unsupplemented mdx control uscle and is indic te by asterisk whereby: * p < 0.05, ** p < 0.01,
and *** p < 0.001 all different from Unsupp; n = 8–10. Asterisk colour denotes the corresponding
subc llular fraction as depicted in the key, and above.
3.2. itochondrial Co-Factors and odulators
3.2.1. oenzy e 10 ( o 10)
Co 10 is an essential cofactor found nat ral y i ractically e ery cell i t .
Co 10 li i -sol ble and primarily acts s an electron carrier in the mitochondrial respiratory
chain. CoQ10 is also a s r ng antioxidant which is able to reduce oxidative radicals and
modulate the mitochondria permeab lity transition pore (MPTP) which could pot tially be of
benefit in DMD muscle to decre se mito hondri l Ca2+ accumulation, swelling, dysfunction nd
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mitochondrially-regulated apoptosis [132]. Previous oral forms of CoQ10 have had limited success at
increasing mitochondrial CoQ10 content due to solubility issues, although recent advances in delivery
(i.e., fast melt formations) have improved mitochondrial uptake and as a consequence, increased
performance [133]. Tissue deficiencies or suboptimal serum levels of CoQ10 have been reported in
a wide range of medical conditions, including cardiomyopathies and degenerative muscular and
neuronal diseases [134–136]. Given DMD patients often develop heart problems as the disease
progresses, but are also characterised by skeletal muscle weakness due to excessive muscle damage,
one potential additional therapy in DMD could be CoQ10 supplementation.
Early studies in dystrophic mice have shown promising results with increases in both physical
performance and survival following CoQ10 administration [137,138]. In human patients, one of the
earliest studies examined CoQ10 administration for a minimum of 40 weeks to an infant (1–2 years
age) and young boy (3–5 years) with preclinical DMD and reported a significant reduction in creatine
kinase, an indirect maker of muscle damage [139]. The first double-blind trial was conducted with
twelve patients, ranging from 7 to 69 years of age, having progressive muscular dystrophies and
neurogenic atrophies including Duchenne, Becker, and limb-girdle dystrophies, myotonic dystrophy,
Charcot-Marie-Tooth disease, and Welander disease. Baseline CoQ10 blood levels were low and
ranged from 0.5 to 0.84 µg¨mL´1. Patients were treated for three months with 100 mg daily of CoQ10
and a matching placebo. Following the supplementation period, improved physical well-being was
observed for half of the CoQ10-treated patients but for none of the placebo patients. Following
crossover, 75% of the initial placebo patients showed improvement with CoQ10-treatment and five of
the six patient who were initially treated with CoQ10 maintained improved cardiac function in the
placebo phase. Only one of the six patients who crossed over from initial CoQ10 to placebo treatment
relapsed. The authors suggested that while effective for the majority of DMD patients, a dosage of
100 mg was potentially too low, albeit effective and safe [140,141].
Recently, a pilot trial was conducted to determine whether the addition of CoQ10 to a stable
steroid regimen could further preserve or increase muscle strength in DMD [142]. Participants
underwent 3 months of lead-in evaluation at their pre-established dose of prednisone, and then began
a CoQ10 dose-finding period at a starting dose of 90 mg CoQ10 daily and a dose escalation of 30 mg
daily until achieving a serum CoQ10 level of 2.5 µg¨mL´1. Following the treatment of an initial
3 patients and failure in achieving desired levels, the initial dose was increased to 400 mg with dose
escalations of 100 mg and delivered in conjunction with a small fatty snack (ice cream). Once the
minimum level was achieved, participants began the 6 month evaluation period, with repeat drug
level monitoring at each visit. Dose adjustments were performed as needed, and reductions were
only performed if there were side effects considered to be related to the drug. The study showed that
the addition of CoQ10 to prednisone treatment in DMD improved muscle strength (8.5%) above and
beyond steroid-related improvements. These limited results suggest further testing of CoQ10 as an
additional therapy in DMD is warranted.
A synthetic analogue of coenzyme Q that is currently employed in the treatment of vascular
and degenerative diseases of the central nervous system is Idebenone (2,3-dimethoxy-5-methyl-6-
(10-hydroxydecyl)-1,4-benzoquinone). Idebenone is a short-chain benzoquinone with strong
antioxidant properties and capacity to improve mitochondrial respiratory chain function and cellular
energy production [143]. Limited studies have examined the therapeutic benefit of Idebenone in
dystrophin-deficient muscular dystrophy. An early preclinical trial examined long term (age 4 weeks
until 10 months) administration in the mdx mouse [144]. In this observer-blinded placebo-controlled
in vivo study, Idebenone treatment was demonstrably cardioprotective and improved voluntary
running performance. Based on the preclinical evidence, a recent phase IIa randomized controlled
clinical trial was conducted to investigate the efficacy and tolerability of Idebenone in children with
DMD, focusing on cardiac and respiratory endpoints [145]. Twenty-one 8–16 year old DMD patients
received either oral Idebenone (150 mg) or matching placebo, three times daily (during meals) for
52 weeks. Idebenone was safe and well tolerated and treatment compliance was excellent. Compared
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to patients on placebo, patients receiving Idebenone showed a trend for improvement of peak systolic
radial strain in the left ventricular inferolateral wall, the region of the heart that is earliest and
most severely affected in DMD. Parameters for respiratory muscle weakness (Peak expiratory flow
(PEF), maximum inspiratory pressure (MIP)) deteriorated in the placebo group but improved in the
Idebenone group, with a statistically significant treatment effect of Idebenone on PEF. An important
limitation of this study was the relative small number of patients, which in combination with the fixed
dose of Idebenone given to a wide range of patient ages and body weights prevented correlation of the
observed effects with drug exposure. Further, the age difference between the treatment and placebo
groups also complicated the interpretation of the study results. Larger randomized controlled studies
are currently ongoing from the same research group to further investigate the potential therapeutic
role of Idebenone in DMD.
3.2.2. Polyphenolic Compounds
Polyphenolic compounds are an exciting new group of potential therapeutic candidates for
DMD and have recently gained popularity due to their antioxidant, anti-inflammatory, cancer
preventative, and cardiovascular benefits [146,147]. Of these compounds, Resveratrol, Quercetin
and epigallocatechin-3-gallate (EGCG) are showing promising results as an effective treatment for
muscular dystrophy.
3.2.3. Resveratrol
Resveratrol (3,5,4’-trihydroxystilbene) is a polyphenolic extract of red wine that is also found
in high concentrations in grape skins and the tree bark and root of certain tree species [148–150].
Resveratrol’s actions are thought to be primarily mediated through the NAD (þ)-dependent
deaceytlase, Sirt1 [151,152]. Resveratrol increases the expression and activity of Sirt1 by molecules
such as AMP-dependent protein kinase [153]. Sirt1 is a nucleocytoplasmic shuttling protein [154] and
its translocation into the nucleus induces superoxide dismutase 2 (Sod2/Mn-Sod), decreases reactive
oxygen species (ROS) levels, and inhibits oxidative stress-induced cell death [155]. Furthermore, both
Resveratrol and Sirt1 activation lead to increased expression of peroxisome-proliferator-activated
receptor-γ co-activator 1 (PGC-1α) [156]. PGC-1α regulates muscle fibre type determination, inducing
a shift from fast to slow fibre type, mitochondrial biogenesis and oxidative capacity [157]. Another
direct downstream target of PGC-1α is utrophin. Utrophin is a dystrophin homolog and is similar
in size and structure to dystrophin [158]. Although it is primarily located at the neuromuscular
junction in adult muscle, it can also functionally take the place of dystrophin throughout the muscle
membrane. Thus the potential for resveratrol to potentiate therapeutic efficacy at both the metabolic
and structural level of dystrophic skeletal muscle is obvious.
Research into the effects of resveratrol in the mdx mouse model of DMD has only been published
within the past 5 years [157,159–164]. Hori et al. [162] supplemented 9 week old mdx mice with
resveratrol (500 mg¨kg´1¨day´1) for 32 weeks and found that resveratrol reduced muscle wasting
(less muscle wasting and non-muscle interstitial tissue deposition in the biceps) compared to mdx
mice fed a control diet. Within the muscle, resveratrol reduced oxidative damage as shown
by the immunostaining of nitrotyrosine and 8-hydroxy-21-deoxyguanosine, and suppressed the
up-regulation of NADPH oxidase subunits Nox4, Duox1, and p47phox. Resveratrol also reduced
the number of α-smooth muscle actin (α-SMA) + myofibroblast cells and endomysial fibrosis in
the biceps femoris. Even though resveratrol did not reduce the secretion of transforming growth
factor-β1 (TGF-β1), a key regulator of collagen deposition and fibrosis, it significantly blocked
TGF-β1 signal transduction.
In addition, Selsby et al. [157] treated 4 week old mdx mice with resveratrol (0 mg¨kg´1¨day´1,
100 mg¨kg´1¨day´1 or 400 mg¨kg´1¨day´1 resveratrol) for 8 weeks. Animals fed a diet containing
100 mg¨kg´1¨day´1 resveratrol demonstrated increased specific force in the fast twitch EDL muscle
and fatigue resistance in the slow twitch soleus muscle, however failed to increase resistance to
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injury in either muscle. Despite improved function, the authors did not investigate resveratrol’s
effect on disease pathology. Furthermore, they also reported that resveratrol did not increase the
protein expression of utrophin. Similar to Hori et al. [162], Selsby et al. [157] administered food orally
and therefore dosage could only be estimated which may explain the reason for lack of increase in
utrophin. It should be noted that that the dosage of 400 mg¨kg´1 administered to the animals resulted
in a number of deaths over the 8 week supplementation period indicating possible toxicity with this
compound. However, since other investigations using this dosage or higher have failed to show this,
it may indicate a source dependent effect rather than an effect of the resveratrol dose, per se [158].
To overcome the lack of dosage precision in previous studies, Gordon and colleagues [163]
supplemented 5 week old mdx mice with resveratrol via oral gavage each day for 10 days. A range
of dosages (0, 10, 100, or 500 mg¨kg´1) were used initially to determine the optimal resveratrol
dosage for Sirt1 activation prior to the beginning of an intervention trial. Similar to Selsby et al. [157],
100 mg¨kg´1 was shown to be most effective, and thus used for subsequent experimental testing. Mdx
results showed that 100 mg¨kg´1 was the only dosage to significantly increase Sirt1 gene expression
and thus further analysis was performed using this dosage. Compared to water treated control,
Resveratrol treatment reduced immune cell infiltration by 21% (assessed via H&E stain) and 43%
(assessed via CD45 immunohistochemistry—a more specific marker of inflammatory cell infiltration),
reduced macrophage infiltration by 48% (assessed via F4/80 immunohistochemistry) and increased
pro inflammatory cytokine IL-6, but not TNF-α. Finally, PGC-1α, and utrophin gene expression were
increased by 27% and 43%, respectively. However, utrophin, Sirt1, and PGC-1α protein content did
not change following 10 days supplementation.
In a follow up study, Gordon et al. [164] recently determined if the beneficial effects observed
in their previous study could be translated into improved muscle function, pathology and oxidative
capacity in young mice. Four to five week old male mdx mice were randomized into control (water)
or Resveratrol-treated groups (100 mg¨kg´1) and dosed every other day for 8 weeks. Resveratrol
mediated substantial improvements in rotarod performance (rotating rod with forced motor activity
being applied) and in-situ peak tension by 53% and 17%, respectively. Slight improvements in
centronucleated fibres and oxidative stress were also observed. Resveratrol did not affect total
immune cell infiltrate at 12 weeks of age, and had no effect on oxidative capacity. Despite the small
changes in muscle pathology, Resveratrol was capable of improving muscle function in mdx mice.
The authors suggest that the likely mechanism is a Resveratrol-mediated reduction in immune cell
infiltrate at the early stages of this disease, which is consistent with their previous findings [163].
Recently, Ljubicic and colleagues [160] demonstrated significantly higher Sirt1 activity and
protein levels, as well as PGC-1α acetylation following 6 weeks of resveratrol supplementation. Using
a similar dosage of 100 mg¨kg´1¨day´1 that has shown to be effective in previous studies, 12 weeks
old mdx mice demonstrated evidence of fibre type transition towards slower, more oxidative fibres
with concomitant increases in mitochondrial biogenesis and expression of slower myosin heavy chain
isoforms. These changes were evoked independent of AMPK signaling-induction. In addition, the
mdx mice were also supplemented with a higher dosage (500 mg¨kg´1¨day´1) for the same period,
but this was less effective and supports previous findings of no added benefit at dosages higher than
100 mg¨kg´1¨day´1.
Finally, protein lysine acetylation/deacetylation is emerging as an important regulatory
mechanism of cellular functions. Transcriptional co-activator P300 acetylates histones and
transcription (co-)factors and controls physiological processes—overexpression of P300 induces
cardiomyocyte hypertrophy in vitro and in vivo, whereas down-regulating P300 ameliorates
cardiomyopathy [165]. Resveratrol has been shown to down-regulate P300 protein levels and thus
may improve the cardiac pathology characteristic of DMD. To explore this concept, 9 week old mice
were fed Resveratrol (4 g¨kg¨meal´1) for 32 weeks [161]. At the age of 41 weeks, pathological
increases in heart weight, the heart weight-to-body weight ratio, and left ventricular cardiomyocyte
diameter were suppressed in Resveratrol-treated mdx mice when compared to untreated mdx and
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control C57BL/10 mice. Furthermore, elevations of atrial natriuretic peptide (ANP) mRNA, a marker
of cardiac hypertrophy, in the mdx heart was also suppressed by resveratrol treatment. Resveratrol
suppressed the increase in myocardial P300 protein level normally seen in mdx mice, but had no
effect on Sirt1 protein and mRNA levels in the heart. Resveratrol also increased histone deacetylase
activity and/or inhibited histone acetyltransferase activity. Although results are promising, more
research is needed to determine if Resveratrol slows or reverses the progression of cardiac dysfunction
administered even after the onset of cardiomyopathy in the dystrophin-deficient heart.
3.2.4. Quercetin
Another natural polyphenolic flavonoid that is a potent activator of Sirt1 is Quercetin. Quercetin
can demonstrably induce deacetylation and activation of PGC-1αwhen taken orally, which stimulates
mitochondrial biogenesis in skeletal muscle [161]. In addition, Quercetin, is an antioxidant and
displays anti-inflammatory characteristics in a variety of cells [161]. Both improved mitochondrial
function and reduced ROS-mediated inflammation via Quercetin supplementation may provide
benefit to dystrophic skeletal muscle. Only two studies to date have published the effects of Quercetin
supplementation on dystrophic muscle—both were performed using the mdx mouse model of the
disease and by the same laboratory group. Hollinger et al. [166] supplemented 3 months old mdx
mice with a 0.2% Quercetin-enriched diet for 6 months and reported various beneficial effects in
the diaphragm compared to unsupplemented controls. Of note, there was a significant reduction in
muscle histopathology whereby muscle fibre number was preserved while inflammation and fibrotic
infiltration was reduced. These improvements occurred alongside increased expression of various
oxidative genes including the mitochondria transcription factor Tfam and the mitochondrial encoded
transcript CoxII, suggesting that increasing the capacity of the mitochondria to produce ATP is key
to reducing the rate of skeletal muscle degeneration in dystrophin-deficient muscle. However, it was
unclear as to whether Quercetin was mediating its effects via a PGC1-α-dependent pathway as the
transcription of downstream targets was comparable to controls, as was utrophin expression which
has been shown to be positively regulated by PGC1-α in gene transfer studies.
In hearts from the same animals [166] and an additional set of 3 weeks old mdx mice that
were supplemented with 0.2% dietary Quercetin until 6 months of age, Ballmann et al. [167]
have demonstrated similar efficacy in attenuating cardiomyopathy. Used as a model in which to
explore the “preventative” efficacy of Quercetin, young mdx mice showed a reduced propensity for
cardiopathology as detected by a 50% reduction in matrix metalloproteinase 9 expression. Increased
mitochondrial density (as inferred by a higher cytochrome c content), utrophin and SOD expression
was also detected in this “preventative” model compared to unsupplemented controls. This suggests
that the protective effects exerted by Quercetin are due to PGC1α-mediated expansion of the
mitochondrial pool and a greater propensity for ROS buffering. In the “rescue” model of older mdx
mice, Quercetin supplementation attenuated ventricular damage and prevented cardiac hypertrophy
compared to unsupplemented controls. This seemed to be related to lower TGF-β1 expression and
not due to a PGC1α-induced response as per the “preventative” model.
While the potential efficacy of quercetin is yet to be investigated in human DMD patients, these
studies in the mdx mouse model show promise and warrant further investigation regarding potential
physiological outcomes and the precise mechanisms via which polyphenols apparently allay skeletal
muscle and cardiac pathology associated with dystrophin deficiency.
3.2.5. Epigallocatechin Gallate (EGCG)
Consumed all over the world, green tea is recognised for its antioxidant and cancer
chemoprevative properties [168]. Made from unfermented leaves, green tea is rich in catechins
polyphenols of which epigallocatechin gallate (EGCG) is the most abundant (30%–50% of total
polyphenols) [169]. Green tea polyphenols (GTP) and its major active constituent EGCG trap
hydroxyl and peroxyl radicals and have shown to be superior ROS scavengers compared to
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vitamins C and E [170–172]. In addition, EGCG may also improve mitochondrial dysfunction
with evidence showing rescued mitochondrial complex I and ATP synthase catalytic activities and
restored oxidative phosphorylation efficiency in cultured lymphoblasts and fibroblasts from Down
syndrome patients [173]. Furthermore, EGCG has been shown to increase Sirt1-dependent PGC-1α
deacetylation, nuclear respiratory factor 1 and mitochondrial transcription factor A protein levels, and
mitochondrial DNA content, concomitant with mitochondrial biogenesis [173]. Although the exact
mechanism of action of GTP and EGCG are not known, current evidence suggests that the benefits
seem to be related to their high antioxidative capacity [171].
Several groups over the past 10 years have investigated the therapeutic effects of GTP mixtures
and EGCG alone via subcutaneous (sc) or oral administration in mdx mice. One Swiss group in
particular (Dr Ruegg’s laboratory), have published a number of papers in this area. In 2002, they
showed that a diet containing 0.01% or 0.05% GTP administered to mdx mice from birth (through their
mother before weaning) significantly reduced necrosis in fast-twitch, but not slow-twitch fibres [174].
In a follow up study, the investigators used a higher dose of GTP (0.25% wt/wt) compared to the
previous study, and also tested the effectiveness of EGCG alone at a dose corresponding to the EGCG
content in the 0.25% GTP group [175]. The mixtures were given via the diet to 3 weeks old dystrophic
mice, either for 1 week to determine if the mixtures could offset the large muscle degeneration that
normally occurs at 3 to 4 weeks of age; or for 5 weeks, to investigate the effects over the proceeding
regeneration period as well (usually completed by 8 weeks of age). Overall, EGCG was slightly more
efficacious compared with GTP, with both substances delaying muscle necrosis and protecting the
EDL muscle but not the soleus muscle (confirming their previous findings of preferential fibre type
effects). The investigators also observed improvements in structural and contractile properties of
the dystrophic muscle, notably force output and resistance to fatigue [175]. The authors concluded
that GTP and EGCG protect muscle cells by scavenging ROS and by improving the antioxidant
(glutathione) balance and reducing oxidative stress [174,176].
In a recent study, Nikae et al. [177] compared administration routes and dosages of EGCG to
determine the most effective for reducing the onset of dystrophic injuries [177]. Over a 5 weeks
period, two groups of 3 weeks old mdx mice were injected sc with either saline or a daily average of
3 or 6 mg/kg EGCG, or fed with either a diet containing 0.1% EGCG (equivalent to 180 mg/kg per
day) or a control diet [177]. At a dosage of 180 mg¨kg´1¨day´1, EGCG administered through the diet
was found to be most effective with significantly better improvements in serum muscle-derived CK,
a marker of muscle damage; isometric force; oxidative stress and fibrosis tissue. No obvious signs of
toxicity were evident. It should be noted, however, that improvements were slightly less than those
observed previously for sc injection when administered immediately after birth [177].
Other studies have confirmed the findings of Ruegg’s laboratory. Subcutaneous injection of
5 mg¨kg´1 EGCG 4 times per week from birth for 8 weeks, has been shown to reduce the phenotypic
onset of muscular dystrophy in mdx mice as evidenced by near normal levels of muscle-derived
CK levels, reduced markers of aging and “wear-and-tear” as indicated by a significant reduction
in fluorescent lipofuscin granules per unit volume of soleus and diaphragm muscles, less fibrosis and
necrotic myofibres, an increased number of normal myofibres, and enhanced expression of utrophin,
a homologue of dystrophin [178]. A diet containing 0.5% GTP given to mdx mice from gestation until
6 weeks after birth increased voluntary wheel running activity and citrate synthase activity (marker
of oxidative capacity) in gastrocnemius muscle, lowered lipid peroxidation (an index of membrane
degradation) in cardiac and gastrocnemius muscles, and decreased sarcolemmal damage [179]. In
another study from the same lab, the histopathology of mdx tibialis anterior muscles was improved
and NF-kB (inflammatory pathway) in the nuclei of the regenerating myofibres was down regulated
using a similar dosage [180].
The results from the aforementioned studies are very promising and suggest that EGCG may
be of benefit for the treatment of DMD patients. In 2010, the first human trial was started with
investigators wanting to examine safety and tolerance of 10 mg¨kg´1 EGCG for 12 weeks, and efficacy
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up to 36 weeks in patients with DMD. The multi-centre, prospective, double blind, placebo controlled,
randomized pilot study is coordinated by Dr. Friedemann of Charite University, Germany, and is due
for completion in 2018.
3.3. Adenine Nucleotide Salvage and de Novo Synthesis Promoters
The maintenance of ATP levels in skeletal muscle is influenced by the balance between
degradation and re-synthesis of the adenine nucleotide pool which is in a constant state of flux.
The energy status of the muscle and the capacity of the metabolic pathways of purine de novo
synthesis and purine salvage in the muscle are primary determinants. In healthy resting muscle,
purine salvage ensures that the majority of the purine nucleotide pool is recovered within the muscle
and not lost via efflux of metabolites into the blood. The enzyme responsible for purine salvage
is Hypoxanthine Guanosine Phosphoribosyl Transferase (HGPRT), which is critical for good health
as demonstrated by the debilitating nature of its absence in Lesch Nyhan Syndrome [181]. During
skeletal muscle metabolic stress and/or catabolism, purine nucleotides can be rapidly degraded to
inosine monophosphate (IMP) and hypoxanthine [182], and, following normal recovery conditions,
up to 90% of the produced hypoxanthine is capably salvaged via the purine nucleotide salvage
pathway [183]. In this pathway, hypoxanthine is recovered to IMP by HGPRT before being converted
to adenylosuccinate by adenylosuccinate synthetase, and subsequently to AMP by adenylosuccinase.
Effective mitochondrial oxidative phosphorylation and sufficient levels of both ADP and AMP
are required for complete repletion of ATP by purine salvage. However, in persistent metabolic
stress and catabolic states such as that evident following intense periods of exercise [182] and in
conditions of pathological wasting associated with DMD [8,28], ATP demand is persistent and
compounds purine base (inosine and hypoxanthine) production and loss from skeletal muscle (which
are subsequently eliminated as uric acid in urine) never to be reclaimed. In this instance, ATP
repletion would be achieved via de novo ATP synthesis via the pentose phosphate pathway (PPP)
in which glucose-6-phosphate is converted to phosphoribosyl-1-pyrophosphate and IMP via a series
of reactions. This is a rate limiting step in the formation of ATP [184] and has been shown to be
improved with ribose feeding [185].
There are fiber type differences in both the degradation and re-synthesis capacities of adenine
nucleotides. Karatzeferis et al. [186] demonstrated that Type II fibres exhibit almost complete
degradation of ATP following a maximal sprint whilst in Type I fibres ATP degradation is
non-existent. A similar effect is observed in rat skeletal muscle where fast-twitch muscle exhibits
greater degradation rates than that of slow-twitch muscle [187]. While the precise metabolic pathways
responsible for the recovery of purines in different muscle fibre types have not been established in
human muscle, the capacity for de novo ATP synthesis is demonstrably slowest in fast-twitch muscle
and fastest in slow-twitch red fibres from the rat [187]. This data highlights that fast-twitch fibres are
at a disadvantage during chronic metabolic stress and therefore more likely candidates for autologous
cell death induction due to the mismatch between purine loss and de novo ATP recovery. This scenario
provides a potential explanation for Type II fibres being preferentially degraded in DMD muscle [188],
and presents an avenue for targeted supplement manipulation of repair and recovery.
At the height of considering DMD as a predominantly metabolic disorder, trial treatments were
aimed at increasing the total adenine nucleotide (TAN) availability by: (1) preventing the loss of
valuable adenine nucleotides; and (2) increasing the supply of metabolites and efficacy of metabolic
pathways and associated support systems. One such trial delivered a cocktail of nucleosides and
nucleotides (adenosine, AMP, ADP, ATP, guanosine, guanosine monophosphate, uridine, uridine
monophosphate and cytidine monophosphate) to 11 DMD boys which showed some improvement
in enzymatic and functional capacity [189]. However, more targeted therapies were approached
following this, which will be discussed hereafter.
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3.3.1. Adenylosuccinic Acid
A seminal study that illustrates the critical role of ATP depletion in dystrophinopathy comprised
a 10 year clinical trial of adenylosuccinic acid (ASA) treatment [190]. ASA stimulates the PNC
producing fumarate to fuel TCA cycling and adenine nucleotides that can increase ADP re-synthesis
and availability to mitochondrial ATP production. Increasing dosage of daily ASA treatment
(25 mg¨kg´1¨day´1 to 600 mg¨kg´1¨day´1) induced vast improvements in a DMD patient who
commenced supplementation from 2.5 years of age. Instantaneous increases in energy, endurance
and stamina were observed following commencement of ASA supplementation with significant
maintenance of muscle strength and function (i.e., able to stand erect, walk without falling and
rise from the floor) noted over the supplementation period. In addition, ASA induced a four-fold
reduction in serum CK levels indicative of reduced muscle damage, and improved the typical
DMD histopathological hallmarks including the ratio of regeneration compared to necrosis [190].
Such improvements in the dystrophic condition readily subsided upon discontinuation of ASA
supplementation highlighting that ongoing support of the mitochondria is pivotal to mitigating
disease progression.
A prominent feature of a muscle biopsy taken from the DMD patient some 4.5 years following
commencement of ASA supplementation was a lack of fatty tissue infiltration. A prominent feature
of dystrophic disease progression is accumulation of fatty tissue [191–193] which may be reflective of
a higher propensity for dystrophic muscle to produce lipids. Culturing of healthy and DMD human
myocytes revealed that in the presence of decreasing concentrations of foetal bovine serum, lipid
production became negligible in healthy cultures while DMD cultures continued to produce lipid
droplets irrespective of serum concentration [193]. The enhanced ability to produce lipid droplets in
DMD myocytes was pinpointed to a dysfunction at the level of isocitrate dehydrogenase in the TCA
cycle—this dysfunction was reportedly eliminated following the addition 1.2 ˆ 10´6 M ASA [194].
ASA’s ability to improve multiple facets of the dystrophic phenotype appears to lie in its capacity to
support both the TCA cycle and the adenine nucleotide pool. These studies importantly highlight
the necessity for further investigation into the ways in which metabolic capacity can be enhanced by
ASA to improve the phenotypic progression of DMD and the quality of life of patients.
3.3.2. Ribose
The pentose monosaccharide, ribose, has been used ostensibly to increase nucleotide recovery
via the purine salvage and de novo synthesis pathways with the ultimate goal of enhancing depressed
cellular ATP levels following exercise [185,195], and in cardiac [196] and various metabolic [195]
diseases. Supplemental ribose acts as an alternative substrate for de novo ATP synthesis by entering
the PPP where it is rapidly converted to ribose-5-phosphate (R-5-P) by ribokinase. R-5-P is
subsequently catalyzed to phosphoribosyl-1-pyrophosphate (PRPP) to increase IMP availability to the
purine salvage pathway. As such, the dependency of de novo ATP synthesis on glucose-6-phosphate
availability and on the rate-limiting function of glucose-6-phsophate dehydrogenase (G-6-PDH)
is eliminated.
While beneficial effects have been observed in healthy individuals recovering from sprint
training regimes [185] as well as patients with myoadenylate deaminase (MAD) deficiency and
McArdles disease (glycogen phosphorylase deficiency) following dietary ribose supplementation,
only one study to date has been performed in DMD patients. Griffiths et al. (1985) supplemented
5 DMD boys aged 6.5 to 11 years with 2 ˆ 250 mg ribose dosages per day over 12 weeks which had
no effect on total muscle phosphorous (including ATP, PCr, Pi, PDi and PCr + Pi) as measured by
31P-NMR, plasma CK levels, muscle strength, or functional measures [197]. However, in this study,
only differences in PCr and Pi were observed between the muscle metabolites of DMD compared to
healthy patients prior to treatment. Importantly, ATP content was shown to be comparable between
DMD and healthy patients and this may be a better reflection of the improved chronic status of the
muscle relative to the acute nature of PCr metabolism—other studies since have demonstrated up
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to 50% reductions in resting ATP levels in DMD skeletal muscle [8]. A notable criticism of this
study was that it used a relatively minor dosage of 250 mg twice daily. Studies is MAD deficient
patients demonstrated that low dose ribose supplementation of 450 mg was ineffective at reducing
exercise-associated soreness and cramping whereas a supplementation rate of 4 g¨dose´1 was proven
beneficial [198,199]. Thus the use of moderate to high dose ribose supplementation warrants further
investigation in DMD.
3.3.3. Allopurinol
In an effort to limit the loss of adenine nucleotides from skeletal muscle as hypoxanthine,
supplementation with allopurinol has been extensively investigated. Allopurinol works via its
metabolite oxipurinol which inhibits the activity of xanthine oxidase in vascular endothelium [200].
This moderates the conversion of purines to uric acid to maintain relatively high plasma
hypoxanthine concentrations relative to the muscle, thereby theoretically reducing the flux of purines
from skeletal muscle. This would afford beneficial effects to dystrophic skeletal muscle by reducing
the need for purine repletion via de novo synthesis and promoting the re-circulation of hypoxanthine
into ATP-synthesis pathways [201]. As there is increased uric acid excretion (and therefore a need
for purine salvage) and a requirement for energy support in DMD patients, supplementation with
allopurinol poses major benefits.
During a 6–12 week trial of 100 mg allopurinol, significant improvements in manual function
was observed which was maintained for a subsequent 6 months [201]. Biochemical studies have
demonstrated similar benefits—following body weight-corrected supplementation of DMD patients,
improvement in levels of metabolites that can stimulate ATP resynthesis was observed [202] with
improvements in the concentrations of ATP [203,204], ADP, GTP, guanosine diphosphate, IMP,
adenylosuccinate, adenine, hypoxanthine and guanine noted following a trial with allopurinol based
on age [203]. This improvement in energy potential was partnered with an increase in the charge
of dystrophic mitochondria from 51% in the placebo group to 83% in allopurinol-treated patients
respectively [203]. This data suggests that the capacity for ATP production is significantly improved
by inhibiting purine catabolism.
In the quadriceps, biceps and adductor muscles, allopurinol supplementation of 10 mg¨kg´1¨day´1
showed either stabilisation or improvement in strength in the DMD patients in the earliest phases of
the disease [205]. As expected, decreased uric acid excretion was observed even in the later stages of
the disease [60]. However, Kulakowski et al. [206] and Tamari et al. [207] only noted functional and
biochemical improvement in some patients (generally in the earlier stage of the disease) following
6 months of therapy [206,207], highlighting that allopurinol therapy might not afford the widespread
benefit that was originally touted.
Numerous researchers have subsequently failed to replicate the beneficial effects of allopurinol
described in previous experiments as an effective treatment for DMD. One of the first to reject the
findings of Thomson and Smith [204] was Bakouche et al. [208] who gave a variety of muscular
dystrophy patients (including DMD) 100 mg of allopurinol daily for a month and 300 mg daily for
a subsequent two months and observed no overall improvement [208]. It should be noted, however,
that the age of patients utilized in this study was in excess of 20 years, which is a significantly
older cohort compared to any other study that had previously investigated allopurinol. Given the
progressive nature of DMD and the relative lifespan of sufferers, it is likely that no treatment would
be beneficial at this stage of disease progression.
In ambulatory dystrophic males from 6 to 12 years of age, no significant improvement
in functional muscle tests or serum CK was observed following supplementation with 100 mg
allopurinol daily for one year [209]. To increase sample size, all 6 patients received allopurinol for
a further 8 weeks to no avail, therefore the authors concluded allopurinol to have no therapeutic
effect [209]. Similarly, following an 8 months 150 mg allopurinol supplementation in dystrophic
boys aged 5 to 13, no clinical improvement, but rather, deterioration was observed in functional
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and strength tests [210] with comparable findings observed following two 3-month trials of 100 mg
allopurinol [211].
In another trial that supplemented allopurinol to 25 DMD boys aged 5–18 years based on weight
(no dose exceeding 150 mg daily) for 12 months, no clinical improvement in muscle and pulmonary
function tests and serum CK and PK levels were observed by the authors despite a decrease in
blood uric acid levels [212]. Furthermore, following daily 200–300 mg doses of allopurinol to 5 DMD
boys aged 6–13 years for 6 weeks [197] and 300 mg daily to 14 DMD boys aged 7–16 years
for 18 months [213], no improvement in phosphate metabolites (including ATP levels), functional
measurements and strength were observed again despite decreased excretion of uric acid. Overall,
these studies report comparable findings using similar assessment techniques and were reported in
quick succession indicating that allopurinol therapy may not be a useful adjunct therapy for the
treatment of DMD.
The majority of studies that have deemed allopurinol therapy to be ineffective for DMD
treatment noted a deterioration of muscle function during and following the supplementation
period [197,210–213]. This may be reflective of the age of participants in these trials and to what
degree the disease had progressed, with the baseline measurements of these studies indicating that
younger patients were able to perform better on functional tests and generally saw some sort of
improvement from allopurinol treatment. Even when young patients are included in clinical trials,
often there is a relatively small age range used (i.e., 6–13 years) that spans a broad range of disease
phenotype within an experimental group (i.e., a 6 years old might still be in a preclinical stage
while a 13 year old may have lost ambulatory capacity). It is well-known that as DMD progresses,
muscle wastage intensifies with the culmination of fibrotic, non-functional muscle and strength
declines [214]. Therefore, the inclusion of DMD patients of older age and who are non-ambulatory
(or thereabouts) limits the potential of such metabolic therapies as there is a significant reduction in
treatable muscle mass. This may explain the conflicting findings and highlights the need for clinical
trials to implement early intervention strategies when considering metabolically-targeted therapies
and their ability to maintain long term efficacy.
4. Summary and Recommendations
Herein, we have reviewed pre-clinical and clinical experimental data derived from both
animal models of, and human patients with, DMD, using numerous metabogenic and nutriceutical
compounds in an attempt to mitigate dystrophinopathy. Through a variety of different intracellular
mechanisms (as summarised in Figure 3), many of these compounds improve various indices of
DMD skeletal muscle pathology. As the majority of the compounds that we have reviewed can be
purchased from nutriceutical suppliers, and therefore readily implemented by parents and health care
providers into established treatment regimens, we thought it was pertinent to categorise the reviewed
compounds according to their level of established therapeutic efficacy and summarise the beneficial
effects of each alongside the most efficacious dosage or dosage range (Table 1). It is our opinion, that
the biggest limiting factor to families and health care providers wanting to make informed decisions
about the suitability and feasibility of implementing such compounds into treatment regimens, is
that there is few efficacy data derived from long term supplementation/treatment strategies (i.e.,
10 years+), As such, it is difficult to identify the effect these compounds have on the long term clinical
progression of DMD. Maintaining realistic expectation regarding the degree of therapeutic efficacy
metabogenic compounds can elicit is therefore, recommended. For example, it would be unrealistic
to presume that the commencement of metabogenic therapy in advanced stage DMD could reverse
the loss of ambulation or cardiomyopathy. In contrast, the implementation of treatment during the
pre-clinical stages could act as a disease modifier to significantly alter the phenotypic course of the
disease, thus having very obvious impacts on patient quality of life.
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Figure  3.  Metabogenic  and  nutriceutical  supplements  to  promote  bioenergetical  potential  and 
moderate muscle wasting in DMD. Dystrophin‐deficient muscle is characterised by the inability to 
produce  sufficient  ATP  to  buffer  increased  (Ca2+),  limit  degeneration  and  to  fuel  regeneration. 
Addition of ATP precursors  (amino acids, ASA,  creatine and  ribose) would expand  the potential 
energy pool and subsequently increase ATP production through stimulation of the various metabolic 
pathways. An additional benefit of AAs would be to augment muscle protein synthesis and inhibit 
macroautophagy  via  direct  stimulation  of  mTOR.  Limiting  the  loss  of  adenine  nucleotides  via 
allopurinol would further expand the potential energy pool and mitigate the need for energy‐consuming 
de novo ATP synthesis. Buffering of ROS‐mediated (CoQ10/Idebenone, polyphenols and taurine) and 
Ca2+‐induced muscle  damage  (creatine  and  taurine)  and  stimulation  of mitochondrial  biogenesis 
(polyphenols)  would  limit  energy  expenditure  on  regeneration  and  augment  bioenergetical 
expansion  of  dystrophic  skeletal  muscle.  Figure  abbreviations:  ADP—adenosine  diphosphate; 
AMP—adenosine  monophoshate;  AMPK—adenosine  monophophate  activated  protein  kinase; 
ASA—adenylosuccinic  acid;  ATP—adenosinie  triphosphate;  Ca2+—calcium;  CK—creatine  kinase; 
Cr—creatine;  Mi‐CK—mitochondrial  creatine  kinase;  mTOR—mammalian  target  of  rapamycin; 
PCr—phosphocreatine; PGC‐1α—peroxisome proliferator‐activated  receptor  gamma  coactivator  1 
alpha;  Pi—inorganic  phosphate;  PNC—purine  nucleotide  cycle;  PNS—purine  nucleotide  salvage 
pathway; ROS—reactive oxygen species; TCA—tricarboxylic acid. 
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Table 1. Categorised summary of metabogenic compound efficacy and dosage for the adjunct treatment of DMD, based upon available literature.
Category Compound Dosage Range Summary of Beneficial Effects Other
Apparently effective/
safe to consume
(in human DMD patients)
Creatine 3–5 g¨day´1
Improved strength, maintenance of











Adenylosuccinic acid 25–600 mg¨kg´1¨day´1
Increased energy, endurance and
stamina, maintenance of muscle
strength and function, reduced
serum CK, reduced muscle necrosis
and enhanced regeneration
Importantly ASA therapy was
administered during preclinical
DMD (2.5 years) and was well
tolerated for 10 years.
Possibly effective
Glutamine 0.5–0.8 g¨kg´1¨day´1 Increased muscle protein synthesisrates following short-term treatment










small reductions in oxidative stress
and muscle fibre damage
Over- or under-dosing limits
efficacy






Current clinical trial is
establishing efficacy and safety at
10 mg¨kg´1¨day´1; Animal data
suggests 180 mg¨kg´1¨day´1
equivalent human dose induces
best benefits, albeit safety not
established at this concentration
Possibly: Reduced serum CK levels,
protection against muscle




production and fatigue resistance
9754
Nutrients 2015, 7, 9734–9767
Table 1. Cont.
Category Compound Dosage Range Summary of Beneficial Effects Other
Too early to tell/unclear
Taurine Not established
Possible benefits include reduced
oxidative stress/ROS damage,
increased muscle contraction force
and strength
L-arginine
Possibly, induction of slow fibre type
transitions & utrophin expression
(protective against damage)
Whey protein isolate Not established Possibly, induction ofmitochondrial biogenesis
Currently on AUS clinical trial




Improved skeletal muscle energy
status, statbilisation or improvement
of muscle strength
Several other trials have found no
effect, Allopurinol might be most
efficacious when combined with
other metabogenic compounds
Not effective/not safe Ribose 500 mg¨day´1 None observed
In other metabolic diseases low dose
therapy (500 mg¨day´1) is
ineffective, but efficacy is observed
at a dosage of 8 g¨day´1
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5. Conclusions
Decades of clinical data suggest the therapeutic value of metabogenic nutriceutical supplements
to promote energy and protein homeostasis in dystrophin-deficient muscle of DMD patients and
animals models of the disease. Although the compounds described throughout this review were used
ostensibly due to their metabogenic potential, it is interesting that very few studies have actually
quantified metabolic changes and the downstream effects on skeletal muscle mass. Thus, while
further work occurs to completely ascertain their efficacy as adjuvant treatments for DMD, these
experiments should endeavor to establish whether metabolic augmentation is a component of any
efficacy. Future experiments should also adopt standardized approaches to accurately compare
efficacy between compounds and compound combinations. Whilst on a molecular level, Ca2+
handling dysregulation and accumulation secondary to the absence of dystrophin is central to the
complex pathophysiology of DMD, it seems that the severe reductions in intracellular energy and
AA status may be the immediate precursors to muscle necrosis, apoptosis and autophagic cell death
pathways. This aspect warrants further attention from a treatment perspective, particularly given that
experimental interventions driven at correcting the genetic cause of the disease are yet to be applicable
to mainstay therapeutics despite several decades of consistent research. We have described the value
of various metabogenic and nutriceutical supplements to adjuvate the treatment of DMD patients.
While promising data has been derived using treatment regimens focused on isolated supplements,
we suggest that greater therapeutic value could be gained from administering combined adjuvants
in supplement regimens designed to target the various deficits and abnormalities evident in the
metabolic milieu that regulates skeletal muscle energy balance and the maintenance of functional
muscle mass.
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